# Jeroen Siemes

> Jeroen Siemes is a Series A investor at BOM (Tilburg) backing Medical Device and Medical. See 8 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [BOM](https://shizune.co/investors/profile/brabantse-ontwikkelings-maatschappij-bom)
- Location: Tilburg, The Netherlands
- Total investments: 8
- Last investment: Sep 2020
- Lead investor: 38%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jeroen-siemes-9679ba29/

Jeroen Siemes is a Series A investor at BOM in Tilburg focused on Medical Device and Medical. Jeroen Siemes is the Senior Investment Manager of Life Sciences and Medtech/Fund to Fund at BOM. Jeroen Siemes attended Tilburg University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical Device | 4 | 50% |
| Medical | 2 | 25% |
| Biotechnology | 2 | 25% |
| Mobile | 1 | 13% |
| Wireless | 1 | 13% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 4 | 50% |
| Series B | 2 | 25% |
| Seed | 1 | 13% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Salvia BioElectronics | Salvia is an innovative startup active in the emerging field of bioelectronics. The name Salvia is derived from the Latin word salvere, which means to stay healthy. In addition, the Salvia-plant has been used to treat headaches, pain, and mental disorders over centuries. Salvia's mission is to deliver bioelectronic solutions that restorehealth for people suffering from chronic migraine. Salvia aims to provide drug-free solutions that are effective and inherently side-effect free and make the novel solutions widely accessible. The Salvia team consists of experienced entrepreneurs, engineers and scientists with diverse professional backgrounds and proven track-record throughout the medical device industry (Sapiens, Medtronic, Philips, St Jude, BioSensors International, Kyphon, etc). | $31M | Series A | Sep 22, 2020 |  |
| Xyall | Xyall is a global innovator in molecular pathology. | $5.5M | Series A | Jan 13, 2020 |  |
| Cytosmart | Cytosmartb develops smart devices to use in laboratories around the world. It provides CytoSMART Lux2, CytoSMART Exact, and CytoSMART Omni for businesses and individuals. The clients of the company are Fontys, THM, Roche, University of Oxford, EMBL, and University of St Andrews. Cytosmart is a Netherlands-based company that was founded in 2012. | $5.5M | Series B | Mar 25, 2019 |  |
| Salvia BioElectronics | Salvia is an innovative startup active in the emerging field of bioelectronics. The name Salvia is derived from the Latin word salvere, which means to stay healthy. In addition, the Salvia-plant has been used to treat headaches, pain, and mental disorders over centuries. Salvia's mission is to deliver bioelectronic solutions that restorehealth for people suffering from chronic migraine. Salvia aims to provide drug-free solutions that are effective and inherently side-effect free and make the novel solutions widely accessible. The Salvia team consists of experienced entrepreneurs, engineers and scientists with diverse professional backgrounds and proven track-record throughout the medical device industry (Sapiens, Medtronic, Philips, St Jude, BioSensors International, Kyphon, etc). | $2M | Seed | Jan 31, 2019 |  |
| Salvia BioElectronics | Salvia is an innovative startup active in the emerging field of bioelectronics. The name Salvia is derived from the Latin word salvere, which means to stay healthy. In addition, the Salvia-plant has been used to treat headaches, pain, and mental disorders over centuries. Salvia's mission is to deliver bioelectronic solutions that restorehealth for people suffering from chronic migraine. Salvia aims to provide drug-free solutions that are effective and inherently side-effect free and make the novel solutions widely accessible. The Salvia team consists of experienced entrepreneurs, engineers and scientists with diverse professional backgrounds and proven track-record throughout the medical device industry (Sapiens, Medtronic, Philips, St Jude, BioSensors International, Kyphon, etc). | $1.4M | Seed | May 23, 2018 |  |
| Mellon Medical | Mellon Medical provides suturing tools for surgeons to improve medical procedures. The company's goal is to help medical specialists improve patient outcomes by providing them with the best possible suturing tools. It commercializes surgical instruments to allow single-handed stitching, enabling efficient and effective suturing of tubular andlayered structures.Mellon Medical was established in 2013 and is headquartered in Nijmegen, Gelderland. | $6.4M | Series B | Aug 30, 2017 |  |
| ATRO Medical | ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype. |  | Series A | Jul 17, 2017 |  |
| Cytosmart | Cytosmartb develops smart devices to use in laboratories around the world. It provides CytoSMART Lux2, CytoSMART Exact, and CytoSMART Omni for businesses and individuals. The clients of the company are Fontys, THM, Roche, University of Oxford, EMBL, and University of St Andrews. Cytosmart is a Netherlands-based company that was founded in 2012. | $1.6M | Series A | Jun 13, 2016 |  |

8 of 8 investments shown.

## Co-investors
- [Thuja Capital](https://shizune.co/investors/profile/thuja-capital) — VC Fund, 5 deals together
- [Holland Capital](https://shizune.co/investors/profile/holland-venture) — VC Fund, 2 deals together
- [Netherlands Enterprise Agency](https://shizune.co/investors/profile/netherlands-enterprise-agency) — VC Fund, 2 deals together
- [BioGeneration Ventures](https://shizune.co/investors/profile/biogeneration-ventures) — VC Fund, 1 deal together
- [Cascara Ventures](https://shizune.co/investors/profile/cascara-ventures) — VC Fund, 1 deal together
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 1 deal together

## About BOM

VC Fund · Tilburg, The Netherlands

BOM invests in innovative start-ups and growth companies. BOM objectives include improved economic growth, increased employment, and solutions to social problems. They offer expertise, resources, and connections through their network to create and finance renewable energy projects.

5 contacts available at BOM.

| Name | Title | Profile |
| --- | --- | --- |
| Gert-Jan Vaessen | Manager | https://shizune.co/investors/profile/gert-jan-vaessen |
| Jeroen Siemes | Senior Investment Manager of Life Sciences and Medtech/Fund to Fund | https://shizune.co/investors/profile/jeroen-siemes |
| Jurgen van Eck | Sr Investment Manager | https://shizune.co/investors/profile/jurgen-van-eck |
| Mercedes Tuin | Sr Investment Manager | https://shizune.co/investors/profile/mercedes-tuin |
| Eelko Brinkhoff | Managing Director Foreign Investments, International Trade and MT member | https://shizune.co/investors/profile/eelko-brinkhoff-abb3 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jeroen Siemes invest in?

Jeroen Siemes invests primarily in Medical Device, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 8 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jeroen Siemes last invest?

The most recent investment recorded for Jeroen Siemes closed in Sep 2020. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co